[{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Genexine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"GX-19N","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hanmi Pharmaceutical \/ Genexine","highestDevelopmentStatusID":"7","companyTruncated":"Hanmi Pharmaceutical \/ Genexine"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"||HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Aptose Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tuspetinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanmi Pharmaceutical \/ Aptose Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Hanmi Pharmaceutical \/ Aptose Biosciences"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"BH3120","moa":"||PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BH3120","moa":"||PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hanmi Pharmaceutical \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HM15211","moa":"GLP-1\/GIP\/Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HM15211","moa":"GLP-1\/GIP\/Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HM15211","moa":"GLP-1\/GIP\/Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Efinopegdutide","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Merck & Co"}]

Find Clinical Drug Pipeline Developments & Deals by Hanmi Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : BH3120 is designed to target PD-L1 on cancer cells and 4-1BB on immune cells. It is being evaluated in combination with pembrolizumab for the treatment of cancer.

                          Product Name : BH3120

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          November 24, 2024

                          Lead Product(s) : BH3120,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The collaboration will support Hanmi in advancing trials for its immuno-oncology drug BH3120 combined with Keytruda in metastatic solid tumors.

                          Product Name : BH3120

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          April 23, 2024

                          Lead Product(s) : BH3120,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Rosuzet is a combination of rosuvastatin is an inhibitor of HMG CoA-reductase, the rate-limiting enzyme that converts the precursor of cholesterol and ezetimibe, a sterol transporter, NPC1L1, which is involved in the intestinal uptake of cholesterol.

                          Product Name : Rosuzet

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 17, 2023

                          Lead Product(s) : Rosuvastatin Calcium,Ezetimibe

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Under the terms of the agreement, Hanmi has granted Aptose exclusive worldwide rights to HM43239 for all indications. HM43239 is a well-tolerated, once-daily oral agent with validated anti-leukemic activity in a highly challenging and heterogeneous malig...

                          Product Name : HM43239

                          Product Type : Other Small Molecule

                          Upfront Cash : $12.5 million

                          September 11, 2021

                          Lead Product(s) : Tuspetinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Aptose Biosciences

                          Deal Size : $420.0 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Genexine 's GX-19N COVID-19 vaccine candidate is a DNA based vaccine and showed no severe side effects. Hanmi will begin producing 10M doses of Genexine’s experimental COVID-19 vaccine with an aim to gradually ramp up production capacity to millions of...

                          Product Name : GX-19N

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 18, 2021

                          Lead Product(s) : GX-19N

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Genexine

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Rolontis," a treatment for neutropenia and "Oraxol," as a treatment for metastatic breast cancer are under priority review by FDA. Hanmi is about to announce the results of their BLA/NDA approval respectively.

                          Product Name : Rolontis

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          January 19, 2021

                          Lead Product(s) : Eflapegrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Spectrum Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The novel drug is under development with the company’s Lapscovery, a platform technology that prolongs the duration of action of biologics, making it possible for patients to take weekly or monthly administration.

                          Product Name : HM15211

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          July 22, 2020

                          Lead Product(s) : HM15211

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercialize efinopegdutidein the United States and globally.

                          Product Name : HM12525A

                          Product Type : Peptide

                          Upfront Cash : $10.0 million

                          April 08, 2020

                          Lead Product(s) : Efinopegdutide

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Merck & Co

                          Deal Size : $870.0 million

                          Deal Type : Licensing Agreement

                          blank

                          09

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Hanmi is planning to begin the global Phase 2 trials of LAPSTriple Agonist in the second quarter this year with biopsy-proven NASH patients.

                          Product Name : HM15211

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          February 28, 2020

                          Lead Product(s) : HM15211

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : HM12525A is the world's first anti-obesity treatment that works as a once-weekly injection. Its efficacy was proven to be higher than existing daily-injection obesity treatment in Phase 2 trials.

                          Product Name : HM15211

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          January 16, 2020

                          Lead Product(s) : HM15211

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank